Stada And Xbrane Receive MHRA Nod For Ranibizumab

Ximluci Biosimilar Rival To Lucentis Will Be Launched ‘During 2023’

 
• By David Wallace
  
MHRA logo on smartphone
The MHRA has approved Ximluci in Great Britain • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Products

More from Generics Bulletin